Lithium NDC 70518-4227

NDC codes

FDA NDC Directory

Product NDC (as listed)70518-4227Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70518-4227Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70518-4227-0	70518422700	10 CUP in 1 BOX (70518-4227-0) / 5 mL in 1 CUP (70518-4227-1)Marketed from Nov 4, 2024
70518-4227-2	70518422702	10 CUP, UNIT-DOSE in 1 BOX (70518-4227-2) / 10 mL in 1 CUP, UNIT-DOSE (70518-4227-3)Marketed from Nov 5, 2024

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lithium
Generic name (nonproprietary): lithium
Active ingredients: Lithium citrate — 8 meq/5mL
Dosage form: Solution
Route: Oral
Labeler: REMEDYREPACK INC.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 218036
Marketing start: Nov 4, 2024
Listing expires: Dec 31, 2027
Identifiers: Product ID 70518-4227_5a5d5889-cbba-dc8e-e063-6294a90a623bSPL ID 5a5d5889-cbba-dc8e-e063-6294a90a623bSPL set ID be1346df-4a39-45e8-874b-e2a496847fd5RxCUI 756059UNII 5Z6E9K79YV
Pharmacologic class: Mood Stabilizer

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470518422700 followed by a unit qualifier and the quantity

Package 70518-4227-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 31, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder: Treatment of acute manic and mixed episodes in patients 7 years and older [see Clinical Studies ( 14 ) ] Maintenance treatment in patients 7 years and older [see Clinical Studies ( 14 ) ] Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder: Treatment of acute manic and mixed episodes in patients 7 years and older ( 1 ) Maintenance treatment in patients 7 years and older ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 218036

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 218036
Product	Strength	Form · route	Labeler	Product NDC
Lithium	Lithium citrate 8 meq/5mL	SolutionOral	Advagen Pharma Ltd	72888-172
Lithium	Lithium citrate 8 meq/5mL	SolutionOral	Atlantic Biologicals Corp.	17856-1172
Lithiumlithium citrate	Lithium citrate 8 meq/5mL	SolutionOral	Precision Dose, Inc.	68094-077